More on FATE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.17 |
|
|||
| Open | $2.13 | ||||
| 52 Wk High | $4.76 | ||||
| 52 Wk Low | $1.46 | ||||
| Day High | $2.17 | ||||
| Day Low | $2.01 | ||||
| P/E | N/A | ||||
| EPS | $-1.91 | ||||
| Volume | 1,064,419 | ||||
- Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis
- Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
- Fate Therapeutics names Jamie Harrell SVP of commercial operations
- Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
- Fate Therapeutics names Jamie Harrell as commercial operations chief
- Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
- Entera Bio adds former Gilead executive Laura Hamill to its board
- Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Entities mentioned with FATE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- S3 | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
